MaxCyte to Provide Updates on First-in-class CARMA™ Platform at BIO Investor Forum
Gaithersburg, Maryland – October 15, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces its planned participation at the BIO Investor Forum in San Francisco, California. CEO & President Doug Doerfler will present 22 October at 11:15 a.m. PT on how MaxCyte is driving the development of the next generation of cell-based medicines with its proprietary CARMA™ platform.
CARMA is MaxCyte’s clinical-stage, non-viral, mRNA-based cell therapy platform that allows for the transfection of mRNA into cells and provides a simple, rapid-to-manufacture, dose-controllable product. CARMA requires less than one day for manufacture therapies for patients, where existing CAR-T therapies require one to two weeks or more to manufacture. MaxCyte’s wholly-owned lead CARMA candidate, MCY-M11, is currently being evaluated in a Phase I clinical trial in patients with advanced ovarian cancer and peritoneal mesothelioma.
The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings. For more information, please visit: //www.bio.org/events/bio-investor-forum
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including six commercial licenses. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com
For further information, please contact:
|MaxCyte Inc.Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer
|+1 301 944 1660|
|Financial PR Adviser
Consilium Strategic Communications
|+44 (0)203 709 5700
|US Media Relations
|+1 410 299 email@example.com|